ENTERO VU 24% Drug Patent Profile
✉ Email this page to a colleague
When do Entero Vu 24% patents expire, and what generic alternatives are available?
Entero Vu 24% is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in ENTERO VU 24% is barium sulfate. One supplier is listed for this compound. Additional details are available on the barium sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENTERO VU 24%?
- What are the global sales for ENTERO VU 24%?
- What is Average Wholesale Price for ENTERO VU 24%?
Summary for ENTERO VU 24%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 32 |
| What excipients (inactive ingredients) are in ENTERO VU 24%? | ENTERO VU 24% excipients list |
| DailyMed Link: | ENTERO VU 24% at DailyMed |
Recent Clinical Trials for ENTERO VU 24%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Laval University | Phase 4 |
| Rigshospitalet, Denmark | Phase 2 |
| Mayo Clinic | Phase 1 |
Pharmacology for ENTERO VU 24%
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for ENTERO VU 24%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | ENTERO VU 24% | barium sulfate | SUSPENSION;ORAL | 208143-008 | May 29, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
